Nintedanib Teva (Nintedanib)

Nintedanib blocks multiple receptor tyrosine kinases such as VEGFR, FGFR and PDGFR. By inhibiting these signals it reduces fibroblast activity, extracellular‑matrix deposition and new blood‑vessel formation, which together help limit fibrotic tissue growth and tumour vascularisation.

The specific dose and dosing schedule of Nintedanib Teva are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Nintedanib during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine‑kinase pathways and also has approved use in certain cancers, whereas pirfenidone’s activity is limited to fibrotic lung disease.

Nintedanib Teva should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Nintedanib Teva is taken orally, usually as a capsule or tablet, with food or as directed by the prescribing physician. Patients should swallow the dose whole with a full glass of water and not crush or split the dosage form unless instructed.

Serious risks include severe liver injury, significant bleeding, arterial thromboembolic events, hypertension, gastrointestinal perforation and serious infections. Patients should report any signs of abdominal pain, unusual bruising, yellowing of the skin or eyes, or sudden severe headaches to their healthcare provider promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, in those with active severe hepatic impairment, and in individuals with uncontrolled bleeding disorders. Caution is also advised for patients with recent major surgery or gastrointestinal ulceration.